Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. In a double-blinded, p...

Full description

Saved in:
Bibliographic Details
Published in:Iranian journal of medical sciences 2017-01, Vol.42 (1), p.14-23
Main Authors: Samadi, Roya, Soluti, Susan, Daneshmand, Reza, Assari, Shervin, Manteghi, Ali Akhoundpour
Format: Article
Language:English
Subjects:
Antidepressants
Antipsychotic drugs
Antipsychotics
Care and treatment
Chi-square test
Clinical trials
Cognitive ability
Comorbidity
Depression
Depression, Mental
Dosage and administration
Drug dosages
Hospitals
Hypotheses
Medicine
Mental depression
Negative symptoms
Neurotransmitters
Obsessive compulsive disorder
Ondansetron
Original
Pathogenesis
Psychiatry
Psychotropic drugs
Registration
Risperidone
Schizophrenia
Serotonin
Statistical significance
Student's t-test
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012-2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4-8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Wechsler's Adult Intelligence Scale-Revised (WAIS-R), and Hamilton's Rating Scale for Depression (HRSD) at baseline and 12 weeks later. Changes in the inventories were used to evaluate the efficacy of the treatment. The t test, Chi-square test, and SPSS (version 16) were used to analyze the data. The statistical significance was set atP
ISSN:0253-0716
1735-3688